Medical Developments International (MVP) has announced that the Decentralized Procedure for its Penthrox methoxyflurane inhaler marketing application has been completed, and the inhaler has been approved in an additional 22 countries. Penthrox has been available in the UK and Ireland, where it is marketed by Galen, and in Belgium and France, where it is marketed by Mundipharma.
The additional approvals are in Austria, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, Germany, Iceland, Italy, Latvia, Lithuania, Luxembourg, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, and Sweden. Mundipharma will market Penthrox in those countries.
MVP CEO John Sharman commented, “The approval of Penthrox for use in Europe is the single biggest achievement in the company’s history. This is a milestone for patients and physicians too: Penthrox can deliver outstanding value against the huge unmet need for fast, easy pain relief for patients who have experienced a trauma injury. By ensuring that a patient’s pain is quickly managed, Penthrox allows healthcare providers to treat the trauma injury faster. This ultimately simplifies the patient journey, helping address the suffering patients experience every day due to under-treatment and inadequate
options for short term relief of moderate and severe trauma pain.”
Mundipharma International Chief Commercial Officer Christian Mazzi said, “This Marketing Authorization is a major step towards bringing Penthrox to people throughout Europe. We’re delighted to be able to continue our proud heritage as leaders in pain management and bring this important new, non-opioid based therapeutic to patients. We look forward to working with the different reimbursement bodies to make sure patients and hospitals have access to Penthrox as soon as possible.”
Read the MVP press release.
